Adagene Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · China
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-04-01$4.61 RISE2026-05-18$3.39 PEAK2026-05-27$4.00 56d | -26.5% 47d | Missed | Missed | — | — | +18.0% 9d | Missed |
DROP2025-09-09$2.50 RISE2026-01-09$1.53 PEAK2026-04-01$4.61 204d | -38.8% 122d | Missed | Missed | — | — | +201.3% 82d | Missed |
DROP2025-09-09$2.50 RISE2025-11-07$1.41 PEAK2026-02-03$2.95 147d | -43.8% 59d | Missed | Missed | — | — | +110.0% 88d | Missed |
DROP2025-08-06$2.37 RISE2025-08-13$1.65 PEAK2025-09-09$2.50 34d | -30.4% 7d | Missed | Missed | — | — | +51.5% 27d | Missed |
DROP2024-12-11$2.12 RISE2025-04-24$1.39 PEAK2025-06-02$2.09 173d | -34.4% 134d | Missed | Missed | — | — | +50.0% 39d | Missed |
DROP2024-10-30$3.15 RISE2025-02-10$1.70 PEAK2025-03-06$2.10 127d | -46.0% 103d | Missed | Missed | — | — | +23.5% 24d | Missed |
DROP2024-09-13$3.49 RISE2024-10-11$2.12 PEAK2024-10-30$3.15 47d | -39.3% 28d | Missed | Missed | — | — | +48.6% 19d | Missed |
DROP2024-09-13$3.49 RISE2024-09-18$2.12 PEAK2024-10-30$3.15 47d | -39.3% 5d | Missed | Missed | — | — | +48.6% 42d | Missed |
DROP2024-06-20$3.10 RISE2024-08-09$2.23 PEAK2024-09-13$3.49 85d | -28.1% 50d | Missed | Missed | — | — | +56.5% 35d | Missed |
DROP2024-02-09$3.68 RISE2024-06-17$2.51 PEAK2024-06-20$3.10 132d | -31.8% 129d | Missed | Missed | — | — | +23.5% 3d | Missed |
DROP2024-01-25$4.15 RISE2024-05-09$2.12 PEAK2024-06-20$3.10 147d | -48.9% 105d | Missed | Missed | — | — | +46.2% 42d | Missed |
DROP2024-01-25$4.15 RISE2024-03-26$2.51 PEAK2024-04-01$3.24 67d | -39.5% 61d | Missed | Missed | — | — | +29.1% 6d | Missed |
DROP2023-10-09$1.83 RISE2023-10-30$1.31 PEAK2024-01-25$4.15 108d | -28.4% 21d | Missed | Missed | — | — | +216.8% 87d | Missed |
DROP2023-06-26$1.76 RISE2023-08-18$1.15 PEAK2023-10-09$1.83 105d | -34.7% 53d | Missed | Missed | — | — | +59.1% 52d | Missed |
DROP2023-02-09$1.90 RISE2023-06-13$1.17 PEAK2023-06-26$1.76 137d | -38.4% 124d | Missed | Missed | — | — | +50.4% 13d | Missed |
1–15 / 23 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company’s focus on improving the therapeutic index of CTLA-4 inhibition
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, N
Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money. Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration with Incyte Corp. (NASDAQ:INCY) to evaluate a novel combination therapy for microsatellite stable colorectal cancer/MSS CRC. The study […]
Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money. Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration with Incyte Corp. (NASDAQ:INCY) to evaluate a novel combination therapy for microsatellite stable colorectal cancer/MSS CRC. The study […]
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patients Triple combination of muzastotug + pembrolizumab + fruquintinib exhibited a dose-dependent response (25% and 40% O
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per
ADAG stock outlook: single-asset bet on ADG126 masked anti-CTLA-4 cancer therapy, with AACR 2026 catalysts, partnerships, and valueâread more macro analysis here.
Adagene Inc. announced the addition of Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board .Peter F. Lebowitz, MD, Ph.D. is currently the Chief Executive Officer of Third Arc...
SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the addition of Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board (SAB). Regarding his appointment to Adagene’s SAB, Lebowitz added, “Adagene’s proprietary SAFEbody masking technology represents an innovative approach to a
Guggenheim analyst Paul Jeng maintains Adagene (NASDAQ:ADAG) with a Buy and raises the price target from $9 to $10.
In late March and early April 2026, Incyte reported positive 54-week Phase 3 data for its JAK1 inhibitor povorcitinib in hidradenitis suppurativa and Adagene announced entering a clinical collaboration with Incyte to test a combination immunotherapy regimen in advanced microsatellite stable colorectal cancer. Together with recent leadership changes, these developments highlight Incyte’s push to build a broader immunology and oncology franchise around both late-stage and early pipeline...
In late March and early April 2026, Incyte reported positive 54-week Phase 3 data for its JAK1 inhibitor povorcitinib in hidradenitis suppurativa and Adagene announced entering a clinical collaboration with Incyte to test a combination immunotherapy regimen in advanced microsatellite stable colorectal cancer. Together with recent leadership changes, these developments highlight Incyte’s push to build a broader immunology and oncology franchise around both late-stage and early pipeline...
SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel antibody-based therapies, today announced the pricing of its underwritten public offering of 18,666,000 American depositary shares, or ADSs, each representing 1.25 ordinary shares of the Company, par value US$0.0001 per share, at the offering price of US$3.75 per ADS, representing the 30-day volume-wei
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration provides additional validation of muzastotug as a potential backbone therapy for next-generation immuno-oncology combinations SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the disco
Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/39) in the combined 10 mg/kg dose cohorts Extended Durability: Median duration of response (mDOR) was not yet reached in the 20 mg/kg cohorts, with responses ongoing beyond 9 months; confirmed mDOR of 6.2 months in the 10 mg/kg cohorts Meaningful Progression-Free Survival (PFS): Me
Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ADAG | +3.93% | +34.12% | +110.05% | +104.64% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +0.96% | +39.84% | +113.50% | +91.95% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 34.5K | $135.37K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2023-04-28 | -0.36 | -0.15 | +58.33% |
| 2022-11-03 | -0.36 | -0.36 | — |
| 2022-08-30 | -0.53 | -0.34 | +35.85% |
| 2022-04-25 | -0.68 | -0.25 | +63.24% |
| 2021-08-25 | -0.44 | -0.32 | +27.27% |
| 2021-03-31 | -0.40 | -0.64 | -57.65% |